WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application
(NDA) for the use of Arimidex (anastrozole) tablets for the treatment
of advanced breast cancer in postmenopausal women who have progressed
following therapy with tamoxifen (Nolvadex).
Arimidex, a nonsteroidal compound, is one of the first of a new
class of selective oral aromatase inhibitors, designed to reduce
the production of estrogen. The NDA is based on randomized, controlled
trials involving 764 women with advanced breast cancer, the company